Granted Patent B2

US 10,780,181 · App. 15/897,835 · Granted Sep 22, 2020

Inventors: Patricius Hendrikus Cornelis Van Berkel (Epalinges, CH); Philip Wilson Howard (Cambridge, GB)

Assignee: MEDIMMUNE LIMITED

A61K47/6849A61K31/5517A61K45/06A61K47/6803C07K16/2803C07K2317/56

Abstract

Claims (16)

1. A conjugate of formula ConjA:

ConjB:

ConjC:

ConjD:

or ConjE:

where Ab is an antibody that binds to CD19, the antibody comprising a VH domain having the amino acid sequence of SEQ ID NO. 1 and a VL domain having the amino acid sequence of SEQ ID NO. 7; and wherein the drug loading is from 1 to 8.

2. The conjugate of claim 1 , wherein the antibody is an intact antibody.

3. The conjugate of claim 1 , wherein the antibody is humanised, deimmunised or resurfaced.

4. The conjugate of claim 1 , wherein the drug loading is 1, 2, 3, or 4.

5. A mixture of the conjugates of claim 1 , wherein the average value of drug loading is about 2 to about 5.

6. The conjugate of claim 1 , wherein said conjugate is ConjE.

7. A pharmaceutical composition comprising the conjugate of claim 1 , and a pharmaceutically acceptable diluent, carrier or excipient.

8. The pharmaceutical composition of claim 7 , further comprising a therapeutically effective amount of a chemotherapeutic agent.

9. A method of treating a CD19 overexpressing cancer comprising administering to a patient the pharmaceutical composition of claim 7 , wherein said conjugate is ConjE.

10. The method of claim 9 , wherein the patient is administered a chemotherapeutic agent; in combination with the conjugate.

11. The method of claim 10 , wherein the chemotherapeutic agent is rituximab.

Assignments (8)

Continuity (7)